Attached files

file filename
S-1 - REGISTRATION STATEMENT - IASO PHARMA INCfs1_iaso.htm
EX-3.1 - CERTIFICATE OF INCORPORATION - IASO PHARMA INCfs1ex3i_iaso.htm
EX-4.10 - COMMON STOCK WARRANT, DATED JANUARY 15, 2009, ISSUED TO PARAMOUNT CREDIT PARTNERS, LLC - IASO PHARMA INCfs1ex4x_iaso.htm
EX-10.10 - EMPLOYMENT AGREEMENT, DATED MAY 17, 2007, BY AND BETWEEN THE REGISTRANT AND MARK LOTZ - IASO PHARMA INCfs1ex10x_iaso.htm
EX-4.6 - FORM OF NOTE PURCHASE AGREEMENT FOR 10% NOTES - IASO PHARMA INCfs1ex4vi_iaso.htm
EX-4.20 - PLACEMENT AGENT WARRANT - IASO PHARMA INCfs1ex4xx_iaso.htm
EX-23.1 - CONSENT OF J.H. COHN LLP - IASO PHARMA INCfs1ex23i_iaso.htm
EX-4.9 - 10% SENIOR PROMISSORY NOTE, DATED JANUARY 15, 2009, ISSUED TO PARAMOUNT CREDIT PARTNERS, LLC - IASO PHARMA INCfs1ex4ix_iaso.htm
EX-3.2 - CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION - IASO PHARMA INCfs1ex3ii_iaso.htm
EX-4.15 - AMENDED AND RESTATED FUTURE ADVANCE PROMISSORY NOTE, DATED SEPTEMBER 30, 2009, ISSUED TO THE LINDSAY A. ROSENWALD 2000 FAMILY TRUSTS DATED DECEMBER 15, 2000 - IASO PHARMA INCfs1ex4xv_iaso.htm
EX-4.7 - FORM OF 10% NOTE - IASO PHARMA INCfs1ex4vii_iaso.htm
EX-4.12 - 10% SENIOR PROMISSORY NOTE, DATED JUNE 24, 2009, ISSUED TO PARAMOUNT CREDIT PARTNERS, LLC - IASO PHARMA INCfs1ex4xii_iaso.htm
EX-4.14 - AMENDED AND RESTATED FUTURE ADVANCE PROMISSORY NOTE, DATED SEPTEMBER 30, 2009, ISSUED TO PARAMOUNT BIOSCIENCES, LLC - IASO PHARMA INCfs1ex4xiv_iaso.htm
EX-10.9 - AMENDMENT, DATED AUGUST 19, 2008, TO EMPLOYMENT AGREEMENT, DATED AS OF JANUARY 19, 2007, BY AND BETWEEN THE REGISTRANT AND JAMES ROCK - IASO PHARMA INCfs1ex10ix_iaso.htm
EX-4.21 - CONSULTANT WARRANT - IASO PHARMA INCfs1ex4xxi_iaso.htm
EX-4.16 - AMENDED AND RESTATED FUTURE ADVANCE PROMISSORY NOTE, DATED SEPTEMBER 30, 2009, ISSUED TO CAPRETTI GRANDI, LLC - IASO PHARMA INCfs1ex4xvi_iaso.htm
EX-4.19 - FORM OF 8% WARRANT - IASO PHARMA INCfs1ex4xix_iaso.htm
EX-3.3 - BY-LAWS - IASO PHARMA INCfs1ex3iii_iaso.htm
EX-4.13 - COMMON STOCK WARRANT, DATED JUNE 24, 2009, ISSUED TO PARAMOUNT CREDIT PARTNERS, LLC - IASO PHARMA INCfs1ex4xiii_iaso.htm
EX-10.12 - LOAN AGREEMENT, DATED AS OF DECEMBER 3, 2008 - IASO PHARMA INCfs1ex10xii_iaso.htm
EX-4.17 - FORM OF NOTE AND WARRANT PURCHASE AGREEMENT FOR 8% NOTES - IASO PHARMA INCfs1ex4xvii_iaso.htm
EX-4.8 - NOTE AND WARRANT PURCHASE AGREEMENT, DATED AS OF JANUARY 15, 2009, BETWEEN THE REGISTRANT AND PARAMOUNT CREDIT PARTNERS, LLC - IASO PHARMA INCfs1ex4viii_iaso.htm
EX-10.7 - EMPLOYMENT AGREEMENT, EFFECTIVE AS OF FEBRUARY 28, 2010, BY AND BETWEEN THE REGISTRANT AND MATTHEW A. WIKLER, MD, MBA, FIDSA - IASO PHARMA INCfs1ex10vii_iaso.htm
EX-4.18 - FORM OF 8% NOTE - IASO PHARMA INCfs1ex4xviii_iaso.htm
EX-10.13 - AMENDMENT NO. 1 TO LOAN AGREEMENT DATED AS OF NOVEMBER 10, 2009 - IASO PHARMA INCfs1ex10xiii_iaso.htm
EX-10.8 - EMPLOYMENT AGREEMENT, DATED AS OF JANUARY 19, 2007, BY AND BETWEEN THE REGISTRANT AND JAMES ROCK - IASO PHARMA INCfs1ex10viii_iaso.htm
Exhibit 4.11

 
NOTE AND WARRANT PURCHASE AGREEMENT

 
This NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made as of the last date set forth on the signature page hereof between PACIFIC BEACH BIOSCIENCES, INC., a Delaware corporation (the “Company”), and Paramount Credit Partners, LLC, a Delaware limited liability company (the “Subscriber”).
 
W I T N E S S E T H:

 
WHEREAS, the Company desires to offer and sell a senior promissory note in an aggregate principal amount of $125,000 in substantially the form attached hereto as Exhibit A (the “Note”) in a private offering (the “Offering”). In addition to the Note, the Subscriber will receive a warrant (the “Warrant”) to purchase shares of Common Stock, $0.001 par value per share (the “Common Stock”), of the Company in the form attached hereto as Exhibit B; and
 
WHEREAS, the Company desires to enter into this Agreement to issue and sell the Note and Warrant and the Subscriber desires to purchase the Note and Warrant on the terms and conditions set forth herein;
 
NOW, THEREFORE, in consideration of the promises and the mutual representations and covenants hereinafter set forth, the parties hereto do hereby agree as follows:

 
I. SUBSCRIPTION FOR NOTES AND REPRESENTATIONS BY SUBSCRIBER
 
1.1 Subject to the terms and conditions hereinafter set forth, the Subscriber agrees to purchase from the Company and the Company agrees to sell and issue to the Subscriber the Note and the Warrant for an aggregate purchase price of $125,000.

 
1.2 The Subscriber recognizes that the purchase of the Note involves a high degree of risk including, but not limited to, the following: (a) the Company has a limited operating history and requires substantial funds in addition to the proceeds of the Offering; (b) an investment in the Company is highly speculative, and only investors who can afford the loss of their entire investment should consider investing in the Company and the Note; (c) the Subscriber may not be able to liquidate its investment; (d) transferability of the Note and the Common Stock underlying the Warrant (sometimes hereinafter collectively referred to as the “Securities”) is extremely limited; (e) in the event of a disposition of the Securities, the Subscriber could sustain the loss of its entire investment; and (f) the Company has not paid any dividends on its capital stock since its inception and does not anticipate paying any dividends in the foreseeable future.

 
1

1.3 The Subscriber represents that the Subscriber is an “accredited investor” as such term is defined in Rule 501 of Regula­tion D (“Regulation D”) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and that the Subscriber is able to bear the economic risk of an invest­ment in the Securities.
 
1.4 The Subscriber hereby acknowledges receipt and careful review of this Agreement, the Note and the Warrant, including all exhibits thereto (collectively referred to as the “Offering Materials”) and hereby represents that the Subscriber has been furnished by the Company during the course of the Offering with all information regarding the Company, the terms and conditions of the Offering and any additional information that the Subscriber, its purchaser representative, attorney and/or accountant has requested or desired to know, and has been afforded the opportunity to ask questions of and receive answers from duly authorized officers or other representatives of the Company concerning the Company and the terms and conditions of the Offering.
 
1.5 The Subscriber hereby represents that the Subscriber, either by reason of the Subscriber's business or financial experience or the business or financial experience of the Subscriber's professional advisors (who are unaffiliated with and not compensated by the Company or any affiliate or selling agent of the Company directly or indirectly), has the capacity to protect the Subscriber's own interests in connection with the transaction contemplated hereby.
 
1.6 The Subscriber hereby acknowledges that the Offering has not been reviewed by the United States Securities and Exchange Commission (the “SEC”) nor any state regulatory authority since the Offering is intended to be exempt from the registration requirements of Section 5 of the Securities Act pursuant to Regulation D promulgated thereunder. The Subscriber understands that the Securities have not been registered under the Securities Act or under any state securities or “blue sky” laws and agrees not to sell, pledge, assign or otherwise transfer or dispose of the Securities unless they are registered under the Securities Act and under any applicable state securities or “blue sky” laws or unless an exemption from such registration is available.
 
1.7 The Subscriber understands that the Securities have not been registered under the Securities Act or any state securities laws by reason of a claimed exemption under the provisions of the Securities Act and such state securities laws that depends, in part, upon the Subscriber's investment intention. The Subscriber hereby represents that the Subscrib­er is purchasing the Securities for the Subscriber's own account for investment and not with a view toward the resale or distribution to others. The Subscriber, if an entity, further represents that it was not formed for the purpose of purchasing the Securities.
 
1.8 The Subscriber understands that there is no public market for the Securities and that no market may develop for any of such Securities. The Subscrib­er under­stands that even if a public market develops for such Securities, Rule 144 (“Rule 144”) promul­gated under the Securities Act requires for non-affiliates, among other conditions, certain holding periods prior to the resale (in limited amounts) of secu­rities acquired in a non-public offering without having to satisfy the regis­tration requirements under the Securities Act. The Subscriber understands and hereby acknowl­edges that the Company is under no obli­ga­tion to register any of the Securities under the Securities Act or any state secu­ri­ties or “blue sky” laws other than as set forth in Article V.

 
2

1.9 The Subscriber consents to the placement of a legend on any certificate or other document evidencing the Warrant and Common Stock that such securities have not been registered under the Securities Act or any state securities or “blue sky” laws and setting forth or referring to the restrictions on transferability and sale thereof contained in this Agreement. The Subscriber is aware that the Company will make a notation in its appropriate records with respect to the restrictions on the transferability of such securities. The legend to be placed on each certificate shall be in form substantially similar to the following:

 
"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "ACT") OR ANY STATE SECURITIES OR "BLUE SKY LAWS", AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR LAWS, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED."

 
1.10 The Subscriber represents that the Subscriber has full power and authority (corporate, statutory and other­wise) to execute and deliver this Agreement and to purchase the Securities. This Agreement constitutes the legal, valid and binding obligation of the Subscriber, enforce­able against the Subscriber in accordance with its terms.
 
1.11 The Subscriber (a) is authorized and qualified to invest in the Company and the person signing this Agreement on behalf of such entity has been duly authorized by such entity to do so and (b) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization.
1.12 Subject to the provision below, the Subscriber hereby agrees that in the case of an initial offering of the Common Stock to the public pursuant to an effective registration statement under the Securities Act (the “IPO”), the Subscriber will not, without the prior written consent of the Company, offer, pledge, sell, contract to sell, grant any option for the sale of, or otherwise dispose of, directly or indirectly, the Registrable Securities (as defined in Section 5.1) purchased or acquired by the Subscriber for a period of up to 180 days from the effective date of the registration statement relating to the IPO.

 
3

1.13 The Subscriber represents and warrants that it has not engaged, consented to or authorized any broker, finder or intermediary to act on its behalf, directly or indirectly, as a broker, finder or intermediary in connection with the transactions contemplated by this Agreement. The Subscriber hereby agrees to indemnify and hold harmless the Company from and against all fees, commissions or other payments owing to any such person or firm acting on behalf of the Subscriber hereunder.
1.14 The Subscriber agrees to hold the Company and its directors, officers, employees, affiliates, controlling persons and agents and their respective heirs, representatives, successors and assigns harmless and to indemnify them against all liabilities, costs and expenses incurred by them as a result of (a) any sale or distribution of the Securities by the Subscriber in violation of the Securities Act or any applicable state securities or “blue sky” laws; or (b) any false representation or warranty or any breach or failure by the Subscriber to comply with any covenant made by the Subscriber in this Agreement or any other document furnished by the Subscriber to any of the foregoing in connection with this transaction.
 
1.15 The Subscriber represents that no authorization, approval, consent or license of any person is required to be obtained for the purchase of the Securities by the Subscriber, other than as have been obtained and are in full force and effect. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, result in any violation of or constitute a default under any material agreement or other instrument to which the Subscriber is a party or by which the Subscriber or any of its properties are bound, or to the best of the Subscriber’s knowledge, any permit, franchise, judgment, order, decree, statute, rule or regulation to which the Subscriber or any of its businesses or properties is subject.
 
1.16 The Subscriber understands, acknowledges and agrees with the Company that the Offering is intended to be exempt from the registration under the Securities Act by virtue of the provisions of Regulation D thereunder, and/or the provisions of Regulation S, which is in part dependent upon the truth, completeness and accuracy of the statements made by the Subscriber.

 
II.
REPRESENTATIONS BY AND COVENANTS OF THE COMPANY

 
The Company hereby represents and warrants to the Subscriber that:

 
2.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has full corporate power and authority to conduct its business as currently conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the property owned or leased by it or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or in good standing would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, operations, conditions (financial or otherwise), properties, assets or results of operations of that entity individually or of the Company and its Subsidiaries (as defined below) as a whole (a “Material Adverse Effect”). For purposes of this Section, “Subsidiary” means any corporation, partnership, limited liability company, association, or other business entity in which the Company owns or controls, directly or indirectly, any interest, including, without limitation, any joint venture, partnership, or similar arrangement.

 
4

2.2 Authorization; Enforceability. The Company has all corporate right, power and authority to enter into this Agreement and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the (i) authorization execution, delivery and performance of this Agreement by the Company; and (ii) authorization, sale, issuance and delivery of the Securities contemplated hereby and the performance of the Company's obligations hereunder has been taken. This Agreement has been duly executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies, and to limitations of public policy. The Note, when issued and fully paid for in accordance with the terms of this Agreement, will be validly issued. The Common Stock issuable upon exercise of the Warrant, when issued in accordance with the terms of the Warrant, will be validly issued, full paid and non-assessable. The issuance and sale of the Securities contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person which have not been waived in connection with this Offering.

 
2.3 No Conflict; Governmental Consents.

 
(a) Except as would not reasonably be expected to have a Material Adverse Effect, the execution and delivery by the Company of this Agreement and the consumma­tion of the transactions contemplated hereby will not result in the violation of any law, statute, rule, regulation, order, writ, injunction, judgment or decree of any court or governmental authority to or by which the Company is bound, or of any provision of the Certificate of Incorporation or By-Laws of the Company, and will not conflict with, or result in a breach or violation of, any of the terms or provisions of, or constitute (with due notice or lapse of time or both) a default under, any lease, loan agreement, mortgage, security agreement, trust indenture or other agreement or instrument to which the Company is a party or by which it is bound or to which any of its properties or assets is subject, nor result in the creation or imposition of any lien upon any of the properties or assets of the Company.

 
(b) No consent, approval, authorization or other order of any governmental authority or other third party is required to be obtained by the Company in connection with the authorization, execution and delivery of this Agreement or with the authorization, issue and sale of the Securities, except as has been obtained or such filings as may be required to be made with the SEC and with any state or foreign blue sky or securities regulatory authority relating to an exemption from registration thereunder.

 
5

2.4 Licenses. Except as would not reasonably be expected to have a Material Adverse Effect, the Company has sufficient licenses, permits and other governmental authorizations currently required for the conduct of its business or ownership of properties and is in all material respects complying therewith.

 
2.5 Litigation. The Company knows of no pending or threatened legal or governmental proceedings against the Company which (i) adversely questions the validity of this Agreement or any agreements related to the transactions contemplated hereby or the right of the Company to enter into any of such agreements, or to consummate the transactions contemplated hereby or thereby or (ii) could, if there were an unfavorable decision, have a Material Adverse Effect. There is no action, suit, proceeding or investigation by the Company currently pending in any court or before any arbitrator or that the Company intends to initiate.

 
2.6 Investment Company The Company is not an “investment company” within the meaning of such term under the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 
2.7 Tax Status. To the best of its knowledge, the Company (i) has made or filed all federal and state income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.

 
2.8 Subordination. Following the Closing Date, as long as the Note remains outstanding, the Company will not, without the Subscriber’s prior written consent, incur indebtedness for borrowed money (“New Debt”) in favor of any person or entity (each a “New Lender”) which indebtedness is secured or otherwise senior in priority to the Note, unless the New Lenders execute and deliver to the Subscriber a subordination agreement providing for the subordination of the New Debt to the Note.
 
III. CLOSING; DELIVERY

 
3.1 The purchase and sale of the Securities shall take place at the offices of Wyrick Robbins Yates & Ponton LLP, 4101 Lake Boone Trail, Suite 300, Raleigh, North Carolina, 27607, at 10:00 a.m., on the date hereof, or at such other time and place as the Company and the Subscriber may mutually agree, orally or in writing (which time and place are designated as the “Closing”).

 
6

3.2 At the Closing, subject to the terms and conditions hereof, the Company will deliver to the Subscriber duly executed copies of the Note and the Warrant dated the date of the Closing (the “Closing Date”), against payment of the purchase price therefor by wire transfer, a check or checks made payable to the order of the Company, a combination of the above, or by such other means as shall be mutually agreeable to the Subscriber and the Company.

 
IV. CONDITIONS TO OBLIGATIONS OF THE PARTIES

 
4.1 The Subscriber’s obligation to purchase the Securities at the Closing at which such purchase is to be consummated is subject to the fulfillment on or prior to the Closing of the following conditions, which conditions may be waived at the option of the Subscriber to the extent permitted by law:

 
(a) Legal Opinion. The Subscriber shall have received an opinion of counsel to the Company addressed to the Subscriber containing certain opinions to be substantially in the form attached hereto as Exhibit C.

 
(b) Officer’s Certificate. The Subscriber shall have received an Officer’s Certificate, signed by the authorized officer of the Company and dated as of the Closing. The certificate shall state, among other things, that the representations and warranties contained herein and in the Offering Materials are true and accurate in all material respects at the Closing Date with the same effect as though expressly made at the Closing Date.

 
V. REGISTRATION RIGHTS

 
5.1 Definitions. As used in this Agreement, the following terms shall have the following meanings.

 
(a) The term “Holder” shall mean any holder of Registrable Securities.

 
(b) The terms “register”, “registered” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or order of effectiveness of such registration statement or document.

 
(c) The term “Registrable Securities” shall mean (i) the shares of Common Stock issuable upon exercise of the Warrant; and (ii) any shares of Common Stock issuable (or issuable upon the conversion or exercise of any warrant, right or other security that is issued) pursuant to a dividend or other distribution with respect to or in replacement of any Securities; provided, however, that securities shall only be treated as Registrable Securities if and only for so long as they (A) have not been disposed of pursuant to a registration statement declared effective by the SEC; (B) have not been sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act so that all transfer restrictions and restrictive legends with respect thereto are removed upon the consummation of such sale; (C) are held by a Holder or a permitted transferee of a Holder pursuant to Section 5.9; and (D) may not be disposed of under Rule 144 under the Securities Act without restriction.

 
7

(d) The term “Trading Event” means the first date on which the Company’s Common Stock trades on a national securi­ties exchange or other automated quotation service, including the Over the Counter Bulletin Board.

 
5.2 Piggyback Registration.

 
(a) The Company agrees that if, at any time, and from time to time, after the earlier to occur of (i) an IPO and (ii) a Trading Event, the Board of Directors of the Company (the “Board”) shall authorize the filing of a registration statement under the Securities Act (other than the IPO or a registration statement on Form S-8, Form S-4 or any other form that does not include substantially the same information as would be required in a form for the general registration of securities) in connection with the proposed offer of any of its securities by it or any of its stockholders, the Company shall: (A) promptly notify each Holder that such registration statement will be filed and that the Registrable Securities then held by such Holder will be included in such registration statement at such Holder’s request; (B) cause such registration statement to cover all of such Registrable Securities issued to such Holder for which such Holder requests inclusion; (C) use best efforts to cause such registration statement to become effective as soon as practicable; and (D) take all other reasonable action necessary under any Federal or state law or regulation of any governmental authority to permit all such Registrable Securities that have been issued to such Holder to be sold or otherwise disposed of, and will maintain such compliance with each such Federal and state law and regulation of any governmental authority for the period necessary for such Holder to promptly effect the proposed sale or other disposition.

 
(b) Notwithstanding any other provision of this Section 5.2, the Company may at any time, abandon or delay any registration commenced by the Company. In the event of such an abandonment by the Company, the Company shall not be required to continue registration of shares requested by the Holder for inclusion, the Holder shall retain the right to request inclusion of shares as set forth above and the withdrawn registration shall not be deemed to be a registration request for the purposes of Section 5.2(c) below.

 
(c) Each Holder shall have the right to request inclusion of any of its Registrable Securities in a registration statement as described in this Section 5.2, up to three times.

 
5.3 Furnish Information. It shall be a condition precedent to the obligation of the Company to take any action pursu­ant to this Article V with respect to the Registrable Securi­ties of any Holder that such Holder shall furnish to the Company such informa­tion regarding the Holder, the Registra­ble Securities held by the Holder, and the intended method of disposition of such securi­ties as shall be reasonably required by the Company to effect the registration of such Holder's Registrable Securities.
 
5.4 Registration Expenses. The Company shall bear and pay all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to registrations pursuant to Section 5.2 for each Holder, including (without limitation) all registration, filing, and qualification fees, printers and accounting fees relating or apportionable thereto (“Registration Expenses”), but excluding underwriting discounts and com­missions relating to Registrable Securities and excluding any professional fees or costs of accounting, financial or legal advisors to any of the Holders.

 
5.5 Underwriting Requirements. In connec­tion with any offering involving an underwriting of shares of the Company's capital stock, the Company shall not be required under Section 5.2 to include any of the Holders' Registrable Securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by it (or by other persons entitled to select the underwrit­ers), and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company. If the total amount of securities, including Registrable Secu­rities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securi­ties, including Registra­ble Securities, which the under­writers determine in their sole discretion will not jeopardize the success of the offering (the securities so included to be appor­tioned pro rata among the selling Holders according to the total amount of securities entitled to be includ­ed there­in owned by each selling Holder or in such other proportions as shall mutu­ally be agreed to by such sell­ing Holders). For purposes of the preceding paren­thetical concerning apportionment, for any selling Holder who is a holder of Registrable Securities and is a partner­ship or corporation, the partners, retired part­ners and stockholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling Holder”, and any pro-rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount of shares carrying registra­tion rights owned by all entities and individuals in­cluded in such “selling Holder”, as defined in this sentence.

 
5.6 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restrain­ing or otherwise delaying any such registration as the result of any controversy that might arise with respect to the inter­pretation or implemen­tation of this Article V.

 
5.7 Indemnification. In the event that any Regis­trable Securi­ties are included in a registration state­ment under this Article V:

 
8

 
 
(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or under­writer within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabili­ties (joint or sever­al) to which they may become subject under the Securities Act, or the Exchange Act, insofar as such losses, claims, damag­es, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collec­tively a “Violation”): (i) any untrue state­ment or alleged untrue statement of a material fact contained in such registra­tion state­ment, including any preliminary prospectus or final prospectus contained therein or any amendments or sup­plements thereto, (ii) the omission or alleged omis­sion to state therein a material fact re­quired to be stated therein, or necessary to make the statements therein not misleading, or (iii) any viola­tion or alleged violation by the Company of the Securities Act, the Exchange Act, or any rule or regulation promulgated under the Securities Act, or the Exchange Act, and the Company will pay to each such Holder, under­writer or controlling person, as in­curred, any legal or other expenses reasonably in­curred by them in connection with investi­gating or defending any such loss, claim, damage, liability, or action; provided, however, that the indemnity agreement contained in this Section 5.7(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability, or action if such set­tlement is effected without the consent of the Compa­ny (which consent shall not be unreasonably with­held), nor shall the Company be liable in any such case for any such loss, claim, damage, liability, or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformi­ty with written information furnished expressly for use in con­nection with such registration by any such Holder, under­writer or controlling person or a violation of any provision of this Agreement by a Holder.

 
(b) To the extent permitted by law, each Holder will indemnify and hold harmless the Company, each of its directors, each of its officers, each person, if any, who con­trols the Company within the meaning of the Securities Act, any underwriter, any other Holder selling securi­ties in such registration statement and any controlling person of any such under­writer or other Holder, against any losses, claims, damages, or liabilities (joint or sever­al) to which any of the foregoing persons may become subject, under the Securities Act, or the Exchange Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information fur­nished by such Holder ex­pressly for use in connection with such regis­tration or a violation of any provision of this Agreement by a Holder; and each such Holder will pay, as incurred, any legal or other expenses reasonably incurred by any person intend­ed to be indemnified pursu­ant to this Section 5.7(b), in connection with investi­gating or defending any such loss, claim, damage, liability, or action; provided, however, that the indem­nity agreement con­tained in this Section 5.7(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is ef­fected with­out the consent of the Hold­er, which consent shall not be unreasonably withheld; provid­ed, further, that, in no event shall any indemnity under this Section 5.7(b) exceed the greater of the cash value of the (i) gross proceeds from the offering received by such Holder or (ii) such Holder’s investment pursuant to this Agreement as set forth on the signature page attached hereto.

 
9

 
(c) Promptly after receipt by an indem­ni­fied party under this Section 5.7 of notice of the commencement of any action (including any governmental action), such indem­nified party shall, if a claim in respect thereof is to be made against any indemnify­ing party under this Section 5.7, deliver to the indemnify­ing party a written notice of the commencement thereof and the indemni­fying party shall have the right to par­ticipate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party simi­larly notified, to assume the defense thereof with counsel selected by the indemnifying party and approved by the indemnified party (whose approval shall not be unreasonably withheld); provided, however, that an indemnified party (together with all other indem­nified parties which may be represented with­out conflict by one counsel) shall have the right to retain one sepa­rate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indem­nified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemni­fied party and any other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a rea­sonable time of the com­mencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indem­nifying party of any liability to the indemnified party under this Section 5.7, but the omission so to deliver written notice to the indemnify­ing party will not re­lieve it of any liabil­ity that it may have to any indem­nified party otherwise than under this Section 5.7.

 
(d) If the indemnification provided for in this Section 5.7 is held by a court of competent juris­diction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or ex­pense referred to therein, then the indemnifying party, in lieu of indem­nifying such indemnified party hereun­der, shall contrib­ute to the amount paid or pay­able by such indemnified party as a result of such loss, liabil­ity, claim, dam­age, or expense in such pro­por­tion as is appro­priate to reflect the relative fault of the indem­nifying party on the one hand and of the indem­nified party on the other in connection with the state­ments or omissions that resulted in such loss, liabili­ty, claim, damage, or expense as well as any other relevant equita­ble consid­er­ations. The relative fault of the indemni­fying party and of the indemnified party shall be deter­mined by refer­ence to, among other things, whether the untrue or alleged untrue statement of a materi­al fact or the alleged omission to state a material fact relates to infor­mation supplied by the indemnifying party or by the indemnified party and the parties' rela­tive intent, knowl­edge, access to infor­ma­tion, and opportunity to correct or prevent such state­ment or omission.

 
(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and con­tri­bution contained in the underwriting agreement en­tered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provi­sions in the underwriting agreement shall con­trol.

 
10

(f) The obligations of the Company and Holders under this Section 5.7 shall survive the com­ple­tion of any offer­ing of Registrable Securities in a registration state­ment under this Article V, and other­wise.

 
5.8 Reports Under Securities Exchange Act of 1934. With a view to making available to the Holders the benefits of Rule 144 and any other rule or regula­tion of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to:

 
(a) make and keep public information avail­able, as those terms are understood and defined in Rule 144, at all times after 90 days after the effective date of the IPO or Trading Event by the Company;

 
(b) file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act; and

 
(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a copy of the most recent annual or quar­ter­ly report of the Company and such other reports and documents so filed by the Company, and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without regis­tration or pursuant to such form.

 
5.9 Permitted Transferees. The rights to cause the Company to register Registrable Securities granted to the Holders by the Company under this Article V may be assigned in full by a Holder in connection with a transfer by such Holder of its Registrable Securities if: (a) such Holder gives prior written notice to the Company; (b) such transferee agrees to comply with the terms and provisions of this Agreement; (c) such transfer is otherwise in compliance with this Agreement and (d) such transfer is otherwise effected in accordance with applicable securities laws. Except as specifically permitted by this Section 5.9, the rights of a Holder with respect to Registrable Securities as set out herein shall not be transferable to any other Person, and any attempted transfer shall cause all rights of such Holder therein to be forfeited.

 
5.10 Termination of Registration Rights The right of any Holder to request inclu­sion in any regis­tration pursuant to Section 5.2 shall terminate if all shares of Registrable Secu­rities held by such Holder may immediately be sold under Rule 144 without restriction.

 
VI. MISCELLANEOUS

 
6.1 Any notice or other communication given hereunder shall be deemed sufficient if in writing and sent by registered or certified mail, return receipt requested, or delivered by hand against written receipt therefor, addressed as follows:

 
11

 
if to the Company, to it at:

 
c/o Paramount Biosciences, LLC
787 Seventh Avenue
48th Floor
New York, NY 10019
Facsimile: (212) 554-4366
Attn: J. Jay Lobell
 

 
With a copy to:

 
Wyrick Robbins Yates & Ponton LLP
4101 Lake Boone Trail
Suite 300
Raleigh, NC 27607-7506
Facsimile: (919)781-4865
Attn: W. David Mannheim, Esq.
Email: dmannheim@wyrick.com
 

 
if to the Subscriber, to it at:

 
Paramount Credit Partners, LLC
787 Seventh Avenue, 48th Floor
New York, NY 10019
Facsimile: (212) 554-4355
Attn: Lindsay A. Rosenwald, M.D.

 
Notices shall be deemed to have been given or delivered on the date of mail­ing, except notices of change of address, which shall be deemed to have been given or delivered when received.

 
6.2 Except as otherwise expressly provided herein, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, either retroactively or prospectively and either for a specified period of time or indefinitely) with the written consent of the Company and the Subscriber.

 
6.3 Subject to the provisions of Section 5.9, this Agreement shall be binding upon and inure to the benefit of the parties hereto and to their respective heirs, legal representatives, successors and assigns. This Agreement sets forth the entire agreement and under­standing between the parties as to the subject matter hereof and merges and supersedes all prior dis­cussions, agreements and understandings of any and every nature among them.

 
12

6. 4 NOTWITHSTANDING THE PLACE WHERE THIS AGREE­MENT MAY BE EXECUTED BY ANY OF THE PARTIES HERETO, THE PARTIES EX­PRESSLY AGREE THAT ALL THE TERMS AND PROVI­SIONS HEREOF SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOV­ERNED BY THE SUBSTANTIVE AND PROCEDURAL LAWS OF THE STATE OF NEW YORK WITH­OUT REGARD TO SUCH STATE’S PRINCIPLES OF CONFLICTS OF LAW. IN THE EVENT THAT A JUDICIAL PROCEEDING IS NECESSARY, THE SOLE FORUM FOR RESOLVING DISPUTES ARISING OUT OF OR RELATING TO THIS AGREEMENT IS THE STATE AND FEDERAL COURTS LOCATED IN THE BOROUGH OF MANHATTAN, STATE OF NEW YORK. THE PARTIES HEREBY IRREVOCABLY CONSENT TO THE JURISDICTION OF SUCH COURTS AND AGREE TO SAID VENUE.

 
6.5 In order to discourage frivolous claims the parties agree that unless a claimant in any proceed­ing arising out of this Agreement succeeds in establishing his claim and recovering a judgment against another party (regardless of whether such claimant suc­ceeds against one of the other parties to the action), then the other party shall be entitled to recover from such claimant all of its reasonable legal costs and expenses relating to such proceeding and/or incurred in prepara­tion therefor.

 
6.6 The holding of any provision of this Agreement to be invalid or unenforce­able by a court of competent juris­diction shall not affect any other provi­sion of this Agreement, which shall remain in full force and effect. If any provision of this Agreement shall be declared by a court of competent jurisdiction to be inval­id, illegal or incapable of being enforced in whole or in part, such provision shall be interpreted so as to remain enforceable to the maximum extent permissible consistent with applicable law and the remaining condi­tions and provisions or portions thereof shall neverthe­less remain in full force and effect and enforceable to the extent they are valid, legal and en­forceable, and no provisions shall be deemed dependent upon any other covenant or provision unless so expressed herein.

 
6.7 It is agreed that a waiver by either party of a breach of any provision of this Agreement shall not operate, or be construed, as a waiver of any subsequent breach by that same party.

 
6.8 The parties agree to execute and deliver all such further documents, agreements and instruments and take such other and further action as may be neces­sary or appropriate to carry out the purposes and intent of this Agreement.

 
6.9 This Agreement may be executed in two or more counter­parts each of which shall be deemed an origi­nal, but all of which shall together constitute one and the same instrument.

 
6.10 Nothing in this Agreement shall create or be deemed to create any rights in any person or entity not a party to this Agreement, except for the holders of Registrable Securities and (b) for the indemnified parties pursuant to Section 5.7 hereof.

 
[REMAINDER OF PAGE INTENTIONALLY BLANK]
 
13


 
IN WITNESS WHEREOF, the undersigned have entered into this Note and Warrant Purchase Agreement as of the 24th day of June, 2009.
 

 
  PACIFIC BEACH BIOSCIENCES, INC.
   
 
By:
/s/ J. Jay Lobell
   
Name:
J. Jay Lobell
   
Title:
 
 

 

 
  PARAMOUNT CREDIT PARTNERS, LLC
   
 
By:
/s/ Lindsay A. Rosenwald, M.D.
   
Name:
Lindsay A. Rosenwald, M.D.
   
Title:
Managing Member
 

 
14